{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:16:09Z","timestamp":1792818969555,"version":"4.5.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Solitary bone plasmacytoma (SBP) and SBP with minimal marrow involvement (SBPmm) are treated similarly with definitive radiation therapy (RT) followed by observation. However, differences in the natural disease course after RT between the two, are not well described. We performed a multicenter study assessing outcomes after RT in 141 patients with SBP and 102 with SBPmm diagnosed between January 2010 and December 2024. About 92% of patients with SBPmm progressed to multiple myeloma (MM) vs 76% of those with SBP (P = .01). Among patients with SBP, 21% progressed with a second solitary bone lesion vs 4% with SBPmm (P&amp;lt; .01). Patients with longer time to progression (TTP) after initial RT could achieve durable responses with RT to a second solitary plasmacytoma in the absence of other myeloma-defining events (MDE). Multifocal lytic bone lesions were the most common MDE, occurring in 89% and 81% of patients with SBPmm and SBP, respectively. Patients with SBPmm had a median TTP of 15 months (95% confidence interval [CI], 14-21) compared to 43 months (95% CI, 34-55) for those with SBP (P&amp;lt; .0001); 67% with SBPmm progressed within 2 years of diagnosis. Del(17p) and 1q+ (gain or amplification) were associated with shorter TTP to MM in SBPmm, with 2-year progression rates of 100% and 82%, respectively. We report significant differences in risk and modes of progression between SBP and SBPmm. Patients with SBPmm are at particularly high risk for early progression to MM, with most developing bone disease as the MDE. These findings support prospective studies incorporating frontline systemic therapy for SBPmm.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019136","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:56:32Z","timestamp":1776880592000},"page":"4286-4295","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2664-116X","authenticated-orcid":false,"given":"Kenneth J. C.","family":"Lim","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"},{"name":"2Division of Hematology, St Vincent\u2019s Hospital Melbourne, Melbourne, Australia"},{"name":"3Division of Hematology, Australian Center for Blood Diseases, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Steinhardt","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"},{"name":"4Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8360-2952","authenticated-orcid":false,"given":"Matthew J.","family":"Rees","sequence":"additional","affiliation":[{"name":"2Division of Hematology, St Vincent\u2019s Hospital Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5536-9011","authenticated-orcid":false,"given":"Patricia","family":"Greipp","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Kelemen","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Baughn","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9488-8212","authenticated-orcid":false,"given":"Amie","family":"Fonder","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Hobbs","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Lisa","family":"Hwa","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0240-0326","authenticated-orcid":false,"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis V.","family":"Kourelis","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-9533","authenticated-orcid":false,"given":"Joselle","family":"Cook","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-1589","authenticated-orcid":false,"given":"Nadine","family":"Abdallah","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-8453","authenticated-orcid":false,"given":"Saurabh","family":"Zanwar","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4640-7311","authenticated-orcid":false,"given":"Mustaqeem A.","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-9933","authenticated-orcid":false,"given":"Ricardo D.","family":"Parrondo","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Medical Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadi","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Medical Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5950-4620","authenticated-orcid":false,"given":"Vivek","family":"Roy","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Medical Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5222-0433","authenticated-orcid":false,"given":"Rachel","family":"Cooke","sequence":"additional","affiliation":[{"name":"7Division of Hematology, Northern Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Dun","sequence":"additional","affiliation":[{"name":"2Division of Hematology, St Vincent\u2019s Hospital Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Zordan","sequence":"additional","affiliation":[{"name":"2Division of Hematology, St Vincent\u2019s Hospital Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slavisa","family":"Ninkovic","sequence":"additional","affiliation":[{"name":"2Division of Hematology, St Vincent\u2019s Hospital Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharene H.","family":"Best","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela A.","family":"Alatorre","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. E.","family":"Wiedmeier-Nutor","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7011-0286","authenticated-orcid":false,"given":"K. Martin","family":"Kortum","sequence":"additional","affiliation":[{"name":"4Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"4Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-8696","authenticated-orcid":false,"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1050-922X","authenticated-orcid":false,"given":"Udit","family":"Yadav","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"12","key":"2026062308465900700_bib1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"2026062308465900700_bib2","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ajh.23201","article-title":"Trends and outcomes of modern staging of solitary plasmacytoma of bone","volume":"87","author":"Warsame","year":"2012","journal-title":"Am J Hematol"},{"issue":"8","key":"2026062308465900700_bib3","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1182\/blood-2014-04-566521","article-title":"Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis","volume":"124","author":"Hill","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2026062308465900700_bib4","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1182\/blood-2014-04-567909","article-title":"Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma","volume":"124","author":"Paiva","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2026062308465900700_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-017-0549-1","article-title":"Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European expert panel","volume":"11","author":"Caers","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2026062308465900700_bib6","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijrobp.2005.06.039","article-title":"Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients","volume":"64","author":"Ozsahin","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2026062308465900700_bib7","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/bjh.13870","article-title":"Clinical features and prognostic factors in solitary plasmacytoma","volume":"172","author":"Finsinger","year":"2016","journal-title":"Br J Haematol"},{"issue":"19","key":"2026062308465900700_bib8","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1002\/cncr.26031","article-title":"Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy","volume":"117","author":"Reed","year":"2011","journal-title":"Cancer"},{"issue":"7","key":"2026062308465900700_bib9","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/bloodadvances.2024013355","article-title":"Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomes","volume":"9","author":"Charalampous","year":"2025","journal-title":"Blood Adv"},{"issue":"8","key":"2026062308465900700_bib10","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ajh.27725","article-title":"Characteristics and survival outcomes of solitary plasmacytomas: a 30-year experience of the Greek Myeloma Study Group on 175 patients","volume":"100","author":"Katodritou","year":"2025","journal-title":"Am J Hematol"},{"issue":"3","key":"2026062308465900700_bib11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1200\/JCO-25-01733","article-title":"Genomics Define Malignant Transformation in Myeloma Precursor Conditions","volume":"44","author":"Maura","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026062308465900700_bib12","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1038\/s41375-025-02699-z","article-title":"Molecular profiling and risk stratification in solitary bone plasmacytoma","volume":"39","author":"Burroni","year":"2025","journal-title":"Leukemia"},{"issue":"12","key":"2026062308465900700_bib13","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1158\/1078-0432.CCR-13-2910","article-title":"Impact of initial FDG-PET\/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma","volume":"20","author":"Fouquet","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2026062308465900700_bib14","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2006-04-015784","article-title":"Immunoglobulin free light chains and solitary plasmacytoma of bone","volume":"108","author":"Dingli","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2026062308465900700_bib15","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1038\/s41467-022-32145-y","article-title":"The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states","volume":"13","author":"Rasche","year":"2022","journal-title":"Nat Commun"},{"issue":"18","key":"2026062308465900700_bib16","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","article-title":"Daratumumab or active monitoring for high-risk smoldering multiple myeloma","volume":"392","author":"Dimopoulos","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"2026062308465900700_bib17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ajh.25755","article-title":"Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: a study of the Greco-Israeli Collaborative Myeloma Working Group","volume":"95","author":"Katodritou","year":"2020","journal-title":"Am J Hematol"},{"issue":"8","key":"2026062308465900700_bib18","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1080\/10428190600647723","article-title":"Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis","volume":"47","author":"Dimopoulos","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2026062308465900700_bib19","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2012.309","article-title":"Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease","volume":"27","author":"Kastritis","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"2026062308465900700_bib20","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"2026062308465900700_bib21","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026062308465900700_bib22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijrobp.2019.10.043","article-title":"Solitary plasmacytoma treated by lenalidomide-dexamethasone in combination with radiation therapy: clinical outcomes","volume":"106","author":"Mignot","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl 1","key":"2026062308465900700_bib23","doi-asserted-by":"crossref","first-page":"12626","DOI":"10.1182\/blood-2022-158528","article-title":"Adjuvant systemic therapy in high risk solitary bone plasmacytoma: results of the UK randomised phase III Idris study (CR UK\/14\/032)","volume":"140","author":"Ediriwickrema","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/12\/4286\/2527404\/blooda_adv-2025-019136-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/12\/4286\/2527404\/blooda_adv-2025-019136-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:47:48Z","timestamp":1782218868000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/12\/4286\/567920\/A-multicenter-study-of-progression-risk-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,6,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019136","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,23]]},"published":{"date-parts":[[2026,6,12]]}}}